Pfizer Inc. has posted lower-than-expected earnings and revenue for the first quarter, in part because of rapidly falling sales of the cholesterol drug Lipitor, Reuters reports.
Sales of the drug, formerly a cash cow for the pharmaceutical giant, plummeted 55 percent to $626 million.
The drug has been competing with cheaper generics since November. Recent health concerns about Lipitor have cropped up as well.
The U.S. Food and Drug Administration has added warnings ...
continue reading...